Jetstream Venture Fund Invests in Rejuvenation Technologies, Expanding its Expanding Longevity and Regenerative Medicine Portfolio
Why now
Thesis: Private longevity bet, no public exposure
Catalyst to watch: Clinical milestones at portfolio company
Main risk: Early-stage biotech failure risk
Why it matters
A venture fund's longevity investment is private-market activity with no direct listed read-through.
Details
SCOTTSDALE, Ariz., Sept. 24, 2026 /PRNewswire/ -- Jetstream Venture Fund (Jetstream), an innovative interval fund dedicated to opening access to institutional-grade deal flow for a wider mainstream audience, today announced a strategic investment in Rejuvenation Technologies. The...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-24 11:09 UTC